###begin article-title 0
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPT1B</italic>
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHKB</italic>
###xml 49 72 49 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
Polymorphism Located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 Haplotype Confer Susceptibility to CNS Hypersomnias (Essential Hypersomnia)
###end article-title 0
###begin p 1
Conceived and designed the experiments: TM MH MK ST KT. Performed the experiments: TM MS. Analyzed the data: TM. Contributed reagents/materials/analysis tools: TM MH MK YH KT. Wrote the paper: TM MH KT.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPT1B</italic>
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHKB</italic>
###xml 50 73 50 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
SNP rs5770917 located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 haplotype were previously identified as susceptibility loci for narcolepsy with cataplexy. This study was conducted in order to investigate whether these genetic markers are associated with Japanese CNS hypersomnias (essential hypersomnia: EHS) other than narcolepsy with cataplexy.
###end p 3
###begin title 4
Principal Findings
###end title 4
###begin p 5
###xml 54 60 54 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">allele</sub>
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>allele</sub></italic>
###xml 69 71 69 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 109 132 109 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 145 155 145 155 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">positivity</sub>
###xml 164 167 164 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;11</sup>
###xml 260 273 260 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501</italic>
###xml 274 283 274 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
EHS was significantly associated with SNP rs5770917 (Pallele = 3.6x10-3; OR = 1.56; 95% c.i.: 1.12-2.15) and HLA-DRB1*1501-DQB1*0602 haplotype (Ppositivity = 9.2x10-11; OR = 3.97; 95% c.i.: 2.55-6.19). No interaction between the two markers (SNP rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype) was observed in EHS.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
CPT1B, CHKB and HLA are candidates for susceptibility to CNS hypersomnias (EHS), as well as narcolepsy with cataplexy.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 97 102 97 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPT1B</italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHKB</italic>
###xml 290 291 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 300 302 300 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 323 326 323 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Miyagawa1">[1]</xref>
###xml 376 381 376 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPT1B</italic>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHKB</italic>
###xml 519 522 519 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Miyagawa1">[1]</xref>
###xml 638 662 638 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA)-DRB1*1501-DQB1*0602</italic>
###xml 673 676 673 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Juji1">[2]</xref>
###xml 678 681 678 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Mignot1">[3]</xref>
###xml 799 808 799 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 810 813 810 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Mignot1">[3]</xref>
###xml 815 818 815 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Langdon1">[4]</xref>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
###xml 613 618 <span type="species:ncbi:9606">human</span>
We previously reported that SNP rs5770917 located between the carnitine palmitoyltransferase 1B (CPT1B) and choline kinase beta (CHKB) genes was associated with susceptibility to narcolepsy with cataplexy after performing a genome-wide association study in Japanese and Korean populations (P = 1.4x10-7; odds ratio = 1.68) [1]. In addition, significantly lower levels of both CPT1B and CHKB mRNA expression were observed in heterozygotes (TC) with the risk allele, as compared to homozygotes (TT) with the major allele [1]. Moreover, it is noteworthy that all narcoleptic patients with cataplexy in Japan carry a human leukocyte antigen (HLA)-DRB1*1501-DQB1*0602 haplotype [2], [3]. Similar findings have been confirmed in individuals of European and African decent for whom the association is with DQB1*0602. [3], [4].
###end p 9
###begin p 10
###xml 245 248 245 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Anderson1">[5]</xref>
###xml 250 253 250 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Mignot2">[6]</xref>
###xml 376 379 376 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Anderson1">[5]</xref>
###xml 381 384 381 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Mignot2">[6]</xref>
###xml 616 617 616 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 662 665 662 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Mignot2">[6]</xref>
###xml 666 669 666 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Honda2">[9]</xref>
###xml 1229 1232 1229 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Honda2">[9]</xref>
###xml 1234 1238 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Komada1">[10]</xref>
###xml 1504 1506 1504 1506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nd</sup>
###xml 1641 1644 1641 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Honda2">[9]</xref>
###xml 1646 1650 1646 1650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Komada1">[10]</xref>
###xml 1745 1768 1745 1768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
Central nervous system (CNS) hypersomnias other than narcolepsy with cataplexy are also complex disorders. Both genetic and environmental factors may contribute to the development of CNS hypersomnias, as in the case of narcolepsy with cataplexy [5], [6]. Identification of the genetic factors has been challenging because of the low prevalence and the difficulty of diagnosis [5], [6]. Although several reports have confirmed the association between some CNS hypersomnias and HLA, HLA typing was performed at the low-resolution serological level, and the association showed marginally statistical significance (0.01<P<0.05) because the number of cases was small [6]-[9]. Thus, in this study, we extended previous association studies to essential hypersomnia (EHS), which is a group of other CNS hypersomnias similar to narcolepsy with cataplexy in the symptom of excessive daytime sleepiness. Our diagnostic criteria for EHS comprised three clinical items: 1) recurrent daytime sleep episodes that occur basically every day over a period of at least 6 months; 2) absence of cataplexy; 3) the condition does not meet the diagnostic criteria of any other disorder causing excessive daytime sleepiness, such as sleep-apnea syndrome [9], [10]. EHS is heterogeneous and consists of several CNS hypersomnias from aborted form of narcolepsy with cataplexy, narcolepsy without cataplexy and a part of idiopathic hypersomnia without long sleep time if we employed International Classification of Sleep Disorders 2nd edition criteria (AASM 2005). Our diagnostic criteria for EHS are focused on the daytime clinical characteristics of CNS hypersomnias [9], [10]. A case-control association study was conducted in order to examine whether SNP rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype are associated with EHS.
###end p 10
###begin title 11
Methods
###end title 11
###begin p 12
###xml 605 608 605 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Honda2">[9]</xref>
###xml 610 614 610 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Komada1">[10]</xref>
###xml 151 163 <span type="species:ncbi:9606">participants</span>
Cases of EHS (n = 137) and Controls (n = 569) were unrelated Japanese living in Tokyo or neighboring areas. Written informed consent was obtained from participants, and the study was approved by the local institutional review boards of all collaborative organizations. Our diagnostic criteria for EHS comprised three clinical items: 1) recurrent daytime sleep episodes that occur basically every day over a period of at least 6 months; 2) absence of cataplexy; 3) the condition does not meet the diagnostic criteria of any other disorder causing excessive daytime sleepiness, such as sleep-apnea syndrome [9], [10].
###end p 12
###begin p 13
###xml 202 205 202 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Miyagawa1">[1]</xref>
###xml 222 230 222 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 235 243 235 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
###xml 843 851 843 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1</italic>
###xml 856 864 856 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DQB1</italic>
Genotyping for SNP rs5770917 in cases was performed using Taqman genotyping assays. For controls, we used the genotype data from the previous genome-wide association study for narcolepsy with cataplexy [1]. Genotyping for HLA-DRB1 and HLA-DQB1 in cases was performed by Luminex Multi-Analyte Profiling system (xMAP) with a WAKFlow HLA typing kit (Wakunaga, Hiroshima, Japan). Briefly, target DNA was amplified by polymerase chain reaction (PCR) with biotinylated primers. The PCR amplicon was then denatured and hybridized to complementary oligonucleotide probes immobilized on fluorescent coded microsphere beads. At the same time, biotinylated PCR products were labeled with phycoerythrin-conjugated streptavidin and immediately examined with Luminex 100 (Luminex, Austin, TX). We did not perform HLA-typing in controls, instead we utilized HLA-DRB1 and HLA-DQB1 frequency data obtained from Japanese Society for Histocompatibility and Immunogenetics databank (a total of 516 Japanese general population were genotyped) ().
###end p 13
###begin p 14
###xml 47 70 47 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
###xml 656 669 656 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501</italic>
###xml 670 679 670 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
The observed associations of SNP rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype were assessed by comparing frequency differences between cases and controls using chi-squared test. Population attributable risk percentage (PAR) for the risk genotypes (SNP rs5770917 C/C and T/C) was evaluated using the following formula, PAR = [p(RR-1)]/[p(RR-1)+1]), where p is calculated based on genotype frequencies in healthy controls and RR indicates relative risk of the risk genotypes. Odds ratio (OR) of the risk genotypes is similar to RR because of the low prevalence of EHS and narcolepsy with cataplexy. Interactions between the two markers (SNP rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype) were calculated based on the positivity of each risk allele in EHS using the correlation coefficient.
###end p 14
###begin title 15
Results
###end title 15
###begin p 16
###xml 220 226 220 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">allele</sub>
###xml 219 226 219 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P<sub>allele</sub></italic>
###xml 235 237 235 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 272 279 272 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005394-t001">Table 1</xref>
###xml 549 556 549 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005394-t002">Table 2</xref>
In order to investigate whether SNP rs5770917 is also a genetic risk marker for the development of EHS, the SNP was genotyped in 137 cases and 569 controls. We found a significant difference between cases and controls (Pallele = 3.6x10-3; OR = 1.56; 95% c.i.: 1.12-2.15) (Table 1). Significant deviation from Hardy-Weinberg equilibrium (HWE) was not observed in either cases or controls. To estimate the epidemiological significance of SNP rs5770917 for EHS development in the Japanese population, PAR was found to be 14.2% in our Japanese samples (Table 2).
###end p 16
###begin title 17
Frequency of SNP rs5770917 in Japanese cases and controls.
###end title 17
###begin p 18
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1 7 1 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">allele</sub>
Pallele was calculated by comparing allele frequency differences in SNP rs5770917 between cases and controls using chi-squared test (one-tailed test).
###end p 18
###begin p 19
RAF, risk allele frequency (C allele); OR, odds ratio; 95% c.i., confidence interval.
###end p 19
###begin p 20
###xml 4 5 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
HWE P represents P value from chi-squared test for Hardy-Weinberg equilibrium.
###end p 20
###begin title 21
Population attributable risk in SNP rs5770917.
###end title 21
###begin p 22
EHS, essential hypersomnia; OR, odds ratio; 95% c.i., confidence interval; PAR, population attributable risk.
###end p 22
###begin p 23
###xml 43 56 43 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501</italic>
###xml 57 66 57 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 128 141 128 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501</italic>
###xml 142 151 142 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 200 201 200 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 201 211 201 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">positivity</sub>
###xml 220 223 220 223 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;11</sup>
###xml 258 265 258 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005394-t003">Table 3</xref>
We also conducted an association study for HLA-DRB1*1501-DQB1*0602 haplotype. Cases carried a significantly higher frequency of HLA-DRB1*1501-DQB1*0602 haplotype than the Japanese general population (Ppositivity = 9.2x10-11; OR = 3.97; 95% c.i.: 2.55-6.19) (Table 3).
###end p 23
###begin title 24
###xml 15 38 15 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
Positivity for HLA-DRB1*1501-DQB1*0602 haplotype.
###end title 24
###begin p 25
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1 11 1 11 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">positivity</sub>
###xml 72 95 72 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
Ppositivity was calculated by comparing the differnce in positivity for HLA-DRB1*1501-DQB1*0602 haplotype between cases and controls using chi-squared test (one-tailed test).
###end p 25
###begin p 26
OR, odds ratio; 95% c.i., confidence interval.
###end p 26
###begin p 27
###xml 61 74 61 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501</italic>
###xml 75 84 75 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DQB1*0602</italic>
###xml 162 163 162 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 173 174 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 172 174 172 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r<sup>2</sup></italic>
The interaction between these two markers (SNP rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype) was then calculated in EHS. No significant interaction was found (P = 0.20; r2 = 0.01), thus suggesting that these markers independently affect susceptibility to EHS.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 133 136 133 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Miyagawa1">[1]</xref>
###xml 442 449 442 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005394-t002">Table 2</xref>
###xml 542 549 542 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005394-t002">Table 2</xref>
###xml 672 679 672 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005394-t001">Table 1</xref>
###xml 681 684 681 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Miyagawa1">[1]</xref>
In the present study, SNP rs5770917, which was identified in our previous genome-wide association study of narcolepsy with cataplexy [1], was also found to confer susceptibility to EHS, a group of other CNS hypersomnias similar to narcolepsy with cataplexy. Thus, the SNP is considered to be a common risk marker for CNS hypersomnias in general. Nevertheless, the OR for narcolepsy with cataplexy (1.92) was greater than that for EHS (1.57) (Table 2). Moreover, PAR for narcolepsy with cataplexy (21.2%) was higher than that for EHS (14.2%) (Table 2), because the risk allele frequency of the SNP in narcolepsy with cataplexy (25.2%) was greater than that in EHS (22.6%) (Table 1) [1].
###end p 29
###begin p 30
###xml 232 236 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-McGarry1">[11]</xref>
###xml 392 395 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">jvs</italic>
###xml 395 398 389 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 560 564 554 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Yoshida1">[12]</xref>
###xml 566 570 560 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Kuwajima1">[13]</xref>
###xml 599 602 593 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">jvs</italic>
###xml 602 605 596 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 662 666 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Chemelli1">[14]</xref>
###xml 668 672 662 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Hara1">[15]</xref>
###xml 694 697 688 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 691 697 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">jvs<sup>&#8722;/&#8722;</sup></italic>
###xml 783 787 777 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Yoshida1">[12]</xref>
###xml 990 994 981 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Tafti1">[16]</xref>
###xml 1155 1159 1143 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Tafti1">[16]</xref>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 635 640 <span type="species:ncbi:10090">mouse</span>
###xml 698 702 <span type="species:ncbi:10090">mice</span>
###xml 766 771 <span type="species:ncbi:9606">human</span>
###xml 797 801 <span type="species:ncbi:10090">mice</span>
###xml 1150 1154 <span type="species:ncbi:10090">mice</span>
CPT1B is the rate-controlling enzyme of long-chain fatty acid beta-oxidation in muscle mitochondria. CPT1B catalyzes the transport of long-chain fatty acyl-CoAs from the cytoplasm into the mitochondria through the carnitine shuttle [11]. Several reports have indicated the role of fatty acid beta-oxidation and carnitine system in sleep regulation. First, fasted juvenile visceral steatosis (jvs-/-) mice with systemic carnitine deficiency exhibit a higher frequency of fragmented wakefulness and rapid eye movement (REM) sleep, and reduced locomotor activity [12], [13]. These phenotypes in fasted jvs-/- mice are similar to those in mouse models of narcolepsy [14], [15]. Moreover, fasted jvs-/- mice are activated by modafinil, which is used for the treatment of human narcolepsy [12]. Second, mice deficient in short-chain acyl-CoA dehydrogenase (encoded by Acads), an enzyme catalyzing the first step of beta-oxidation, have shown significantly slower theta frequency during REM sleep [16]. Administration of acetyl-L-carnitine, which is known to restore beta-oxidation in the mitochondria, significantly recovers slow theta frequency in mutant mice [16].
###end p 30
###begin p 31
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Aoyama1">[17]</xref>
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Kent1">[18]</xref>
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Zweigner1">[19]</xref>
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Fioravanti1">[20]</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Dixon1">[21]</xref>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Nishino1">[22]</xref>
###xml 551 556 551 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPT1B</italic>
###xml 561 565 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHKB</italic>
CHKB catalyzes the first phosphorylation reaction in the CDP-choline pathway for phosphatidylcholine synthesis [17]. Phosphatidylcholine is the major membrane phospholipid in mammalian cells [18] and inhibition of phosphatidylcholine synthesis triggers apoptosis in the brain [19]. CDP-choline, which is used in the treatment of disorders of a cerebrovascular nature [20], increases acetylcholine release [21]. Acetylcholine is a known REM- and wake-promoting neurotransmitter that increases narcolepsy symptoms [22]. Thus, either of these two genes (CPT1B and CHKB) is a plausible candidate for susceptibility to CNS hypersomnias (EHS), as well as narcolepsy with cataplexy.
###end p 31
###begin p 32
###xml 220 223 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Mignot2">[6]</xref>
###xml 224 227 224 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005394-Honda2">[9]</xref>
###xml 346 347 346 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 347 357 347 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">positivity</sub>
###xml 366 369 366 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;11</sup>
To date, reports on the association between HLA and CNS hypersomnias other than narcolepsy with cataplexy have been based on serological typing and small sample size, thus yielding only marginal statistical significance [6]-[9]. In this study, we found a highly significant association between HLA and EHS using DNA-based high-resolution typing (Ppositivity = 9.2x10-11), suggesting an immunological pathogenesis for EHS.
###end p 32
###begin p 33
###xml 275 298 275 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
###xml 364 387 364 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
###xml 258 266 <span type="species:ncbi:9606">patients</span>
It is important to examine the interaction between SNP rs5770917 and HLA with regard to susceptibility to CNS hypersomnias. However, it is impossible to calculate the interaction between SNP rs5770917 and HLA in narcolepsy with cataplexy, because almost all patients possess HLA-DRB1*1501-DQB1*0602 haplotype. No interaction was observed between SNP rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype, suggesting that they are independent risk factors for not only EHS but also narcolepsy with cataplexy.
###end p 33
###begin p 34
###xml 128 133 128 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CPT1B</italic>
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHKB</italic>
###xml 335 358 335 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
###xml 527 550 527 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA-DRB1*1501-DQB1*0602</italic>
###xml 311 319 <span type="species:ncbi:9606">patients</span>
EHS analyzed in this study have recurrent daytime sleep episodes but do not have cataplexy. Thus, SNP rs5770917 located between CPT1B and CHKB might be involved in the pathogenesis of excessive daytime sleepiness, not cataplexy. Although our cases are heterogeneous, as exemplified by the findings that not all patients with EHS carry HLA-DRB1*1501-DQB1*0602 haplotype, SNP rs5770917 is considered to be a common risk marker for both HLA positive and negative EHS, because no interaction was observed between SNP rs5770917 and HLA-DRB1*1501-DQB1*0602 haplotype.
###end p 34
###begin p 35
Our data suggest that EHS, a group of heterogeneous CNS hypersomnias similar to narcolepsy with cataplexy, might be in continuity with narcolepsy with cataplexy in common genetic background.
###end p 35
###begin title 36
References
###end title 36
###begin article-title 37
Variant between CPT1B and CHKB associated with susceptibility to narcolepsy.
###end article-title 37
###begin article-title 38
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.
###end article-title 38
###begin article-title 39
Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.
###end article-title 39
###begin article-title 40
Genetic markers in narcolepsy.
###end article-title 40
###begin article-title 41
Idiopathic hypersomnia: a study of 77 cases.
###end article-title 41
###begin article-title 42
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
###end article-title 42
###begin article-title 43
###xml 143 151 <span type="species:ncbi:9606">patients</span>
A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness.
###end article-title 43
###begin article-title 44
HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy.
###end article-title 44
###begin article-title 45
Difference in the characteristics of subjective and objective sleepiness between narcolepsy and essential hypersomnia.
###end article-title 45
###begin article-title 46
The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis.
###end article-title 46
###begin article-title 47
###xml 110 114 <span type="species:ncbi:10090">mice</span>
Fasting-induced reduction in locomotor activity and reduced response of orexin neurons in carnitine-deficient mice.
###end article-title 47
###begin article-title 48
Reduced Carnitine Level Causes Death from Hypoglycemia: Possible Involvement of Suppression of Hypothalamic Orexin Expression During Weaning Period.
###end article-title 48
###begin article-title 49
###xml 30 34 <span type="species:ncbi:10090">mice</span>
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.
###end article-title 49
###begin article-title 50
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.
###end article-title 50
###begin article-title 51
Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep.
###end article-title 51
###begin article-title 52
Structure and function of choline kinase isoforms in mammalian cells.
###end article-title 52
###begin article-title 53
CTP:phosphocholine cytidylyltransferase.
###end article-title 53
###begin article-title 54
Bacterial inhibition of phosphatidylcholine synthesis triggers apoptosis in the brain.
###end article-title 54
###begin article-title 55
Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly.
###end article-title 55
###begin article-title 56
Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release.
###end article-title 56
###begin article-title 57
###xml 27 32 <span type="species:ncbi:9606">human</span>
Pharmacological aspects of human and canine narcolepsy.
###end article-title 57
###begin p 58
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 58
###begin p 59
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study is supported by Grant-in-Aid for Scientific Research on Priority Areas "Comprehensive Genomics" and "Applied Genomics" from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Grant-in-Aid for JSPS fellows and Astellas Foundation for Research on Metabolic Disorders. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 59

